Analyst predicts slow start for Leo Pharma's Adtralza in UK

The take-up of Leo Pharma’s atopic eczema drug Adtralza in the UK will be slow-going, according to analyst bureau Global Data, after the British institute NICE released draft guidance where it was not recommend it as a standard treatment in England and Wales.

Photo: Leo Pharma / PR

Leo Pharma shouldn’t count on big sales of its atopic eczema drug Adtralza on the UK market – at least not to begin with.

Analyst bureau Global Data came to this conclusion after the UK’s National Institute for Health and Care Excellence (NICE), which works with the National Health Service (NHS) in England to provide treatment guidance for England and Wales, issued draft guidance where the treatment was not recommended as a standard treatment for atopic dermatitis.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs